Pierre Kemula, B.Sc. has been our Chief Financial Officer since November 2024. He previously served as the Chief Financial Officer of Nasdaq listed biotech Company, CureVac N.V. from October 2016 to November 2024. Prior to this, Mr. Kemula was Chief Financial Officer of Euronext listed Pixium Vision from May 2014 to September 2016, and Vice
Ellen Lefever has been our General Counsel since July 2021. She previously served as Deputy General Counsel at Galapagos from April 2019 to June 2021 and as Legal Counsel at Galapagos from May 2014 to April 2019. Prior to this, from September 2007 to April 2014, she worked at corporate law firms Linklaters, Simpson, Thacher
Paul van der Horst has been our Chief Business Officer since May 2021 and was our Chief Financial Officer between May 2024 and November 2024. Prior to joining AgomAb, he was Head of Corporate Development at Galapagos NV (Nasdaq: GLPG), or Galapagos, from April 2019 to April 2021. From March 2016 to March 2019, he
Andrea Sáez has been our Chief Development Officer since November 2023 and was previously our Head of Portfolio Development from January 2022 to November 2023. Prior to joining AgomAb she was Chief Operating Officer from July 2021 to January 2022 and Chief Scientific Officer from September 2020 to January 2022 at Origo Biopharma S.L., or
Philippe Wiesel has been our Chief Medical Officer since January 2021. Previously, from August 2010 to December 2020, Dr. Wiesel was the Chief Medical Officer at Genkyotex SA, a clinical development company developing treatment for fibrotic disorders in the liver, lung, and kidney, which was acquired by Calliditas Therapeutics AB in 2021. Prior to this
Tim Knotnerus has been our Chief Executive Officer since February 2019 and member of our Board of Directors since March 2021. Prior to AgomAb, Mr. Knotnerus held positions of increasing responsibility at AM-Pharma B.V., most recently as Vice President of Corporate Development from June 2012 to April 2020. Prior to that, Mr. Knotnerus was a
Recent Comments